Skip to main content
logo
Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
31.47
+1.06 (3.49%)
At close: Jan 21, 2026, 4:00 PM EST
31.50
+0.03 (0.10%)
After-hours: Jan 21, 2026, 4:10 PM EST

Company Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo.

Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Forte Biosciences, Inc.
Forte Biosciences logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees16
CEOPaul A. Wagner

Contact Details

Address:
3060 Pegasus Park Drive, Building 6
Dallas, Texas 75247
United States
Phone310 618 6994
Websitefortebiorx.com

Stock Details

Ticker SymbolFBRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1419041
CUSIP Number34962G109
ISIN NumberUS34962G2084
Employer ID26-1243872
SIC Code2834

Key Executives

NamePosition
Dr. Paul A. Wagner Ph.D.Chief Executive Officer, President and Chairman
Antony A. Riley CPAChief Financial Officer
Dr. Barbara K. Finck M.D.Chief Medical Clinician and Director
Christopher RoenfeldtChief Operating Officer

Latest SEC Filings

DateTypeTitle
Jan 20, 2026SCHEDULE 13GFiling
Jan 9, 2026SCHEDULE 13G/AFiling
Dec 23, 2025SCHEDULE 13GFiling
Nov 14, 2025SCHEDULE 13G/AFiling
Nov 14, 2025SCHEDULE 13G/AFiling
Nov 14, 202510-QQuarterly Report
Nov 14, 20258-KCurrent Report
Oct 7, 2025SCHEDULE 13G/AFiling
Sep 30, 2025S-8Securities to be offered to employees in employee benefit plans
Sep 5, 2025SCHEDULE 13G/AFiling
View All SEC Filings